Heart failure & cardiomyopathies
Bromocriptine in Peripartum Cardiomyopathy: A Meta-Analysis with Trial Sequential Analysis
Authors' conclusion
In this meta-analysis with TSA, the use of bromocriptine with standard care was associated with improved LV function and remodelling in patients with PPCM compared with standard care alone, with a similar effect on mortality and re-hospitalization.
Study context
- Population
- Patients with peripartum cardiomyopathy (PPCM)12 studies (2 randomized controlled trials (RCTs), 10 observational)
- Participants
- 1,765 patients
- Comparison
- Bromocriptine plus standard care vs standard care alone
- Bromocriptinen = 474
- Standard caren = 1,291reference
- Outcome
- Left ventricular (LV) function and dimensions
Methodological detailstrial sequential analysis
- Trial sequential analysis
Pooled result
As reported in the abstract
Bromocriptine vs Standard careMD, % (95% CI)P value
LVEF
9.98(2.86–17.10)
P < 0.001Bromocriptine vs Standard careMD, cm (95% CI)P value
LV end-diastolic diameter
−2.51(−4.23 to −0.79)
P = 0.004LV end-systolic diameter
−5.61(−10.03 to −1.18)
P = 0.010Bromocriptine vs Standard careOdds ratio (95% CI)P value
Improved LV function; reported as higher proportion with bromocriptine
0.35(0.16–0.75)
P = 0.007Further pooled results
Major adverse cardiovascular events (MACE), all-cause mortality, HF rehospitalization
- No significant differences between groups
Trial sequential analysis
- LVEF and diastolic dimension reached the required information size; only LVEF crossed the monitoring boundary
Original publication
Bromocriptine in Peripartum Cardiomyopathy: A Meta-Analysis with Trial Sequential Analysis. ESC Heart Fail. Published 10 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →